G

GIPathfinder

Rigidizing overtube enhances GI endoscope control

Overview

Pathfinder develops a rigidizing overtube to improve endoscope control during gastrointestinal (GI) procedures. It addresses endoscope looping by allowing the overtube to instantly switch from flexible to rigid, stabilizing the endoscope and making navigation easier in complex cases and altered anatomy. The product works by being placed over the endoscope during a procedure; in flexible mode it slides with the scope, and when rigidity is needed, it becomes stiff to prevent looping, guiding the scope more precisely. Pathfinder differentiates itself from competitors by offering a quick toggle between flexible and rigid states, focusing specifically on GI procedures such as luminal therapeutics and ERCP, and targeting improved procedural efficiency and success rates in hospitals and clinics. The company aims to improve procedural outcomes, shorten procedure times, and enhance patient care by providing a reliable solution to endoscope looping that supports clinicians in difficult cases.

Work here?Claim your company

About GIPathfinder

Simplify's Rating
Why GIPathfinder is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Company Size

51-200

Company Stage

Series D

Total Funding

$97M

Headquarters

Burlingame, California

Founded

2016

Get referred to GIPathfinder

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 CARE-1 showed 100% cecal intubation and zero adverse events.
  • DDW 2026 presence and late-breaking data signal active commercial and clinical momentum.
  • 2024’s $97 million Series D funded expansion, while Pathfinder usage reportedly keeps growing.

What critics are saying

  • Triton remains investigational in 2026; commercial success depends on future FDA clearance.
  • GIPathfinder’s clinical story relies on Neptune Medical; branding confusion can dilute employer credibility.
  • Single-product dependence makes Pathfinder vulnerable if adoption stalls or competitor overtubes outperform.

What makes GIPathfinder unique

  • Pathfinder’s Dynamic Rigidization™ toggles flexible-to-rigid instantly during GI procedures.
  • FDA-cleared Pathfinder reached market in 2021, unlike most experimental endoscopy robotics.
  • Olympus participated in Neptune Medical’s 2024 Series D, validating strategic relevance.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$97M

Above

Industry Average

Funded Over

1 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
$80M
$97M
$100M

Benefits

  • Health Insurance
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • Remote Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Professional Development Budget
  • Conference Attendance Budget
  • Stock Options
  • Company Equity
  • Wellness Program

Growth & Insights and Company News

6 month growth

1%

1 year growth

1%

2 year growth

22%
WTWH Media LLC
Oct 4th, 2024
Robotics Investments Near $1B In August

Listen to this articleSwiss-Mile raised $22M in August 2024 for its wheeled quadruped. Fifty producers of robots and robotics enabling technologies received funding in August 2024, pulling in a total of approximately $1 billion. This figure is on par with the $1.2 billion average The Robot Report has tracked each of the previous 12 months. Investment targeted to robotics companies for the first eight months of 2024 equals about $10.86 billion. You can follow The Robot Report‘s investment section here. The largest investments in August were secured by developers of autonomous driving technologies

Business Wire
Aug 17th, 2024
Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Neptune Medical announces $97 million in Series D financing, along with the spinout of its Jupiter Endovascular subsidiary.

Recently Posted Jobs

Sign up to get curated job recommendations

GIPathfinder is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs